Azithromycin-d3 , ≥98atom%D , 163921-65-1
| Pack Size | Price | Stock | Quantity |
| 50mg | RMB2455.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 125-1290C |
| storage temp. | -20°C Freezer, Under Inert Atmosphere |
| solubility | Chloroform (Slightly, Sonicated), Methanol (Slightly) |
| form | Solid |
| color | White to Off-White |
| EPA Substance Registry System | 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-6-(methyl-d3)-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (163921-65-1) |
Description and Uses
Azithromycin-d3 is intended for use as an internal standard for the quantification of azithromycin (Item No. 15004) by GC- or LC-MS. Azithromycin is a macrolide antibiotic. It is active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC90s = <0.01-2 mg/L). Azithromycin increases survival in mouse models of intraperitoneal S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED50s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively). It inhibits replication of severe acute respiratory coronavirus 2 (SARS-CoV-2), but not Middle East respiratory syndrome CoV (MERS-CoV), when used at concentrations of 5 and 10 μM. Azithromycin also decreases plasma levels of IL-6, TNF-α, and IL-1β and increases survival in a mouse model of LPS-induced sepsis when administered at a dose of 100 mg/kg. Formulations containing azithromycin have been used in the treatment of a variety of bacterial infections.
AzithroMycin-d3 can be used as Semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial.;AzithroMycin-d3 can be intended for use as an internal standard for the quantification of Azithromycin by GC- or LC-mass spectrometry.
